CD8A and cancer: Most of the tumour-derived CD8+ T cell epitopes for which we have structural information are derived from the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) cancer/testis antigen expressed in a range of cancers, and therefore are a great target for immunotherapeutic design [37,38].